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Background: Expression of the long non-coding RNA (lncRNA) LOC285194 was previously shown to be correlated
with aggressive clinicopathological features and poor prognosis in several cancers. The aim of the present study
was to explore the relationship between LOC285194 expression and clinical outcomes in esophageal squamous cell
carcinoma (ESCC), so as to assess whether it could be a novel biomarker for prognosis and prediction of response
to therapy on ESCC patients.
Methods: The method of quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure
LOC285194 expression in pretreatment biopsy specimens and matched normal tissue derived from ESCC patients
who underwent preoperative chemoradiotherapy followed by surgical resection (CRT + S group; n = 55) or from
those who received surgical resection alone (S group; n = 87). The association between LOC285194 expression and
clinicopathological features and prognosis were then analyzed.
Results: LOC285194 expression was significantly down-regulated in ESCC tumor tissues when compared with the
adjacent normal tissues (p < 0.001). Low expression of LOC285194 was associated with larger tumor size (p = 0.002),
advanced TNM stage (p = 0.018), more lymph node metastases (p = 0.013) and distant metastases (p = 0.015). In the
CRT + S group, the pathological complete response rate was 57% (16/28) for the LOC285194-high group, and
15% (4/27) for the LOC285194-low group. Univariate analysis revealed that low expression of LOC285194 was
significantly correlated with CRT response (p = 0.002). Moreover, Kaplan-Meier survival analysis revealed that patients
with low expression of LOC285194 had a decreased disease free survival (DFS) (p < 0.001) and overall survival (OS)
(p < 0.001). Multivariable analysis further identified low expression of LOC285194 as an independent prognosis factor
for CRT response (p = 0.011), DFS (p < 0.001) and OS (p = 0.002).
Conclusion: Decreased expression of LOC285194 could serve as a molecular marker to predict the clinical outcome
of ESCC patients after surgery, and select patients who would benefit from preoperative CRT.
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In Eastern Asia, 90% of the esophageal cancers are eso-
phageal squamous cell carcinoma (ESCC) [1]. When
treated exclusively by surgery, the prognosis of patients
with ESCC is poor, with 5-year survival rates ranging
from 9%–40% [2]. Although preoperative chemoradio-
therapy (CRT) is commonly recommended by many
physicians to improve the rate of curative resection and
prolong survival, the clinical outcomes from randomized
trials are equivocal [3-5]. Indeed, patients with the same
pathological types and the same clinical stages show sig-
nificantly different survival benefits after the identical
treatment. It has been previously reported that patients
with pathological complete response (pathCR) have a
better clinical outcome than those with less than pathCR
[6]. Therefore, the identification of molecular markers
related to tumor response to CRT could help to select
patients who are most likely to benefit from the pre-
operative CRT.
Long non-coding RNAs (lncRNAs) represent a new
class of non- protein-coding RNAs which are longer
than 200 bases, and do not function as templates for
protein synthesis [7]. Previous studies have proved that
lncRNAs play a critical role in the development and pro-
gression of cancer [8]. Additionally, multiple studies
have indicated that the expression levels of lncRNAs are
dysregulated in different kinds of tumors, including
ESCC [9], and the aberrant expression of lncRNAs are
correlated with metastasis, recurrence and prognosis.
Specifically, the lncRNA HOTAIR has been shown to
play a role in breast cancer, MALAT1 has been related
to lung cancer, and HULC is reported to contribute to
liver cancer [10-12]. Recently, the relatively new field of
lncRNA research has focused on their value in the diag-
nosis and treatment of cancer. Indeed, it has been sug-
gested that lncRNAs may serve as molecular markers for
diagnosis, prognosis and prediction of tumor response
to treatment [13].
The lncRNA LOC285194 (Gene ID: 285194), also
called LSAMP antisense RNA 3, consists of four exons
with 2105 bases in length. It was first reported to be
within a tumor suppressor unit in osteosarcoma and de-
pletion of this lncRNA promoted proliferation of normal
osteoblasts through regulation of apoptotic and cell cycle
transcripts as well as VEGF receptor 1 [14]. Decreased
of LOC285194 expression has been reported in several
cancers, and was strongly associated with malignant
potential and poor patient prognosis [14-16]. However,
to date, the association between this lncRNA expression
and the prognosis of patients with ESCC has not been
elucidated. In this study we examined the expression
level of LOC285194 in ESCC tumors tissues and adja-
cent normal tissues. The relationships between its ex-
pression and clinicopathological features were thenanalyzed so as to evaluate whether LOC285194 expres-
sion could be a useful biomarker for prognosis and pre-
diction of response to therapy in ESCC patients.
Materials and methods
Patients and samples
One hundred and forty-two tumor tissues and paired ad-
jacent normal samples were obtained from patients who,
based on the biopsy specimens, were diagnosed with
ESCC at Nanjing Hospital Affiliated to Nanjing Medical
University (n = 64) and Huai’an First Hospital Affiliated
to Nanjing Medical University (n = 78) between January
2009 and November 2010. All of the specimens were
immediately frozen in liquid nitrogen and then stored
at –80°C until RNA extraction. Of the 142 patients with
ESCC, 55 (39%) patients underwent surgical treatment
four or five weeks after completion of preoperative CRT
(CRT + surgery [CRT + S] group). The remaining 87
(61%) patients were administered with surgical resection
alone (S group). All patients were selected in the study
based on the following inclusion criteria: biopsy spe-
cimens were identified as ESCC by histopathological
examination; no previous treatment had been received;
no T4 or T1N0 tumors; and no evidences of distant organ
metastasis. The clinical stage was determined according to
the 7th edition of tumor-node-metastasis (TNM) classifi-
cation for esophageal carcinoma (UICC, 2009). Written
informed consent was obtained from all patients and the
study was approved by the Ethics committee of Nanjing
Hospital of Nanjing Medical University and Huai’an First
Hospital of Nanjing Medical University.
Treatment
CRT + S group: Each patient underwent the same pre-
operative concurrent CRT which included a 5-fluorouracil
(5-FU) based regimen. Specifically, cisplatin (20 mg/m2/
day, for 5 days, IV) and 5-FU (500 mg/m2/day, for 5 days,
24 h continuous infusion) were administered on days 1–5.
Standard premedications were used. Radiotherapy was
performed on the first day of the first chemotherapy cycle.
A total radiation dose of 40 Gy was given in 20 fractions
of 2 Gy each, with 5 fractions per week for 4 weeks. Four
or five weeks after completion of CRT, a standard
thansthoracic en bloc esophagectomy with two-field
lymph node dissection was performed.
S group: The surgical approach was the same as that
described for the CRT + S group.
Evaluation and follow-up
The histopathological response to CRT was classified
into four categories according to the following criteria:
grade 1, no evidence of viable tumor cells; grade 2, <10%
viable tumor cells; grade 3, 11–50% viable tumor cells;
grade 4, >50% viable tumor cells [17]. We then divided
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complete response (pathCR) group, which consisted of
grade 1, and the < pathCR group, which consisted of
grades 2–4.
All patients were followed every 3 months during the
first year, every 6 months for an additional 2 years, and
then every year until March 2014.
Cell lines and cell culture
This study used five human ESCC cell lines (KYSE30,
KYSE 70, KYSE 150, KYSE510 and Eca109) and one nor-
mal human esophageal epithelial cell (Het-1A). All the
cells were generous gifts from Dr. Zhi-hua Liu at the
State Key Laboratory of Molecular Oncology, Cancer
Institute, Chinese Academy of Medical Sciences (Beijing,
China) [9]. These cells were grown in RPMI-1640
(Invitrogen, Carlsbad, CA) medium supplemented with
10% fetal bovine serum (Gibco, Grand Island, NY) and
1% penicillin-streptomycin at 37°C with 5% CO2.
RNA isolation and cDNA synthesis
Total RNAs were extracted from tumor tissues and adja-
cent normal tissues using Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. The yield and quality of total RNA was eva-
luated by measuring the absorbance at 260 and 280 nm.
Only samples with an A260:A280 ratio between1.8 and 2.1
was considered for further analysis. cDNAs were synthe-
sized using the PrimeScript™ RT reagent kit with gDNA
Eraser (Takara, Dalian, China) according to the ma-
nufacturer’s protocol. Briefly, 1 μg total RNA, 2 μl 5×
gDNA Eraser Buffer, 1 μl gDNA Eraser and RNase Free
dH2O, were combined in a total reaction volume of
10 μl and incubated at 42°C for 2 min to eliminate the
genomic DNA. Ten microliters of reverse-transcription
reaction mixture (consisted of 4 μl 5× PrimeScript Buffer
2, 1 μl PrimeScript RT Enzyme Mix 1, 1 μl RT Primer
Mix, and 4 μl RNase Free dH2O) was then added, and
the mixture was incubated at 37°C for 15 min, followed
by 85°C for 5 s to generate the cDNA.
Quantitative real-time PCR (qRT-PCR)
The expression of LOC285194 was quantified using
SYBR® Premix Ex Tag™ II (Takara, Dalian, China) accor-
ding to the manufacturer’s instructions on the ABI 7500
Real-Time PCR System (Applied Biosystems, Foster City,
CA). Briefly, the 20 μl reaction mixtures were incubated
at 95°C for 30 s for the initial denaturation stage,
followed by 40 cycles at 95°C for 5 s and 60°C for 34 s.
GAPDH was used to normalize the target gene expres-
sion. The ΔCt method was used to calculate the relative
expression of LOC285194 in ESCC tumor tissues or ESCC
cell lines in comparison with paired normal tissues or
cells, respectively. Each sample was examined in triplicate.The primers used in this study were synthesized by
Invitrogen with the sequences as follows: 5′- TGTG
CCTGTTTGACCTCTGA-3′(sense) and 5′-AGGAAG
GATAAA AGACCGACCA -3′(antisense) for LOC285
194; 5′-TGCACCACCAACTGCTTAGC-3′(sense) and
5′-GGCATGGACTGTGGTCATGAG -3′ (antisense) for
GAPDH.
Statistical analysis
All statistical analyses were performed using the Statis-
tical Program for Social Sciences (SPSS) 20.0 software.
Overall survival (OS) was defined as the time from regis-
tration to death or until last follow-up date. Disease free
survival (DFS) was calculated from registration to detec-
tion of tumor recurrence or until last follow-up date.
The correlation between LOC285194 expression and
clinicopathological characteristics were evaluated by the
χ2 test. DFS and OS were calculated by Kaplan-Meier
survival analysis and compared by the log rank test. To
assess the factors that influenced the CRT response,
multiple logistic regression analysis was performed on
the factors that were shown to be significant on univa-
riate analysis. All statistical analysis were two sided and
p values less than 0.05 were considered significant.
Results
Patient characteristics
Patient clinicopathological characteristics were shown in
Table 1. The cohort comprised 48 females and 94 males,
with an average age of 64.5 years (range, 41 to 75). In
the S group, clinical stages of the 87 patients were as
follows: 13 cases, stage IIA; 21 cases, stage IIB; and 53
cases, stage III.
In the CRT + S group, all 55 patients underwent the
same preoperative concurrent CRT regimen. Twenty pa-
tients achieved pathCR, and the less than pathCR was
observed in the remaining 35 patients.
Of the 142 patients with ESCC, the median follow-up
time was 23 months (range, 3 – 36 months), with 97
(68%) tumor recurrence and 89 (63%) cancer-related
death.
Expression of LOC285194 in ESCC
To assess whether LOC285194 expression was asso-
ciated with clinicopathologic characteristics in ESCC, we
first measured its expression level by qRT-PCR in 142
paired tumor samples and adjacent non-tumor tissues.
We detected that LOC285194 expression was signifi-
cantly down-regulated in tumor tissues when compared
to the adjacent normal tissues (p < 0.001; Figure 1A).
Approximately 69% (98/142) of the tumor samples
had >2-folds lower LOC285194 expression than that in
non-tumor tissues. Furthermore, we also examined the
level of LOC285194 in five ESCC cell lines and one
Table 1 Correlation between LOC285194 expression and
clinicopathologic characteristics of 142 ESCC patients
Variables LncRNA LOC285194 subgroupa Pb value
Low High
All cases 71 71
Gender
Male 49 (69.1%) 45 (63.3%) 0.478
Female 22 (30.0%) 26 (36.7%)
Age (years) 0.614
≤55 8 (11.3%) 10 (14.1%)
>55 63 (88.7%) 61 (85.9%)
Tumor size (cm) 0.002*
≤5 39 (55.0%) 57 (80.3%)
>5 32 (45.0%) 14 (19.7%)
Tumor location 0.573
Cervical/upper thoracic 6 (8.5%) 8 (11.3%)
Middle/lower thoracic 65 (91.5%) 63 (88.7)
Histologic grade 0.022*
G1 6 (8.5%) 7 (9.9%)
G2 36 (50.7%) 50 (70.4%)
G3/G4 29 (40.8%) 14 (19.7%)
Smoking status 0.603
Ever/current 28 (39.4%) 25 (35.2%)
Never 43 (60.6%) 46 (64.8%)
Alcohol consumption 0.206
Ever/current 17 (23.9%) 11 (15.5%)
Never 54 (76.1%) 60 (84.5%)
T status 0.27
T1/2 18 (25.4%) 24 (33.8%)
T3/4 53 (74.6%) 47 (66.2%)
N status 0.013*
N0M0 23 (32.4%) 39 (54.9%)
N1M0 22 (31.0%) 19 (26.8%)
M1-lymc 26 (36.6%) 13 (18.3%)
M status 0.015*
M0 45 (63.4%) 58 (81.7%)
M1-lym 26 (36.6%) 13 (18.3%)
Clinical stage 0.018*
IandII 26 (36.6%) 40 (56.3%)
III 45 (63.4%) 31 (43.7%)
CRT response 27 28 0.001*
PathCRd 4 (29.6%) 16 (67.9%)
Less than PathCR 23 (70.4%) 12 (32.1%)
aMedian expression level was used as a cutoff to divide the 142 patients
into LOC285194 low group (n = 71) and LOC285194 high group (n = 71).
bChi-square test. cM1-lym, distant lymph node metastasis. dPathCR, pathologic
complete response. *p < 0.05.
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cell lines, the LOC285194 level was lower in 3(KYSE30,
KYSE510, Eca109) as compared with the normal esopha-
geal epithelial cell (p < 0.05; Figure 1B), but no statistical
differences were observed for KYSE70 and KYSE150.
LOC285194 expression and clinicopathological
characteristics
To further analyze whether there was an association bet-
ween LOC285194 expression and specific clinicopatholog-
ical parameters in patients with ESCC, we then used the
median expression level of LOC285194 as a cutoff to
divide the 142 patients into LOC285194-high (n = 71, with
an average ΔCt expression value of 8.29) and low groups
(n = 71, with an average ΔCt expression value of 11.96).
We found that the LOC285194-low group was sig-
nificantly associated with larger tumor size, worse histo-
logic grade, advanced TNM stage, and more lymph node
metastasis and distant metastases (p < 0.05; Table 1).
However, statistical association between LOC285194
expression and other clinicopathological data including
gender, age, tumor location, smoking status, alcohol con-
sumption and depth of invasion released no significant
differences (p > 0.05; Table 1).
Correlation between LOC285194 expression and
pathological response to CRT
We next sought to explore whether LOC285194 ex-
pression could be a predictable molecular marker for CRT
response on ESCC patients. We first investigated the asso-
ciation between LOC285194 expression level and patho-
logical response to CRT in the CRT + S group. Of the 55
patients, the pathCR rate was 57% (16/28) in the
LOC285194- high group, while it was only 15% (4/27) in
the LOC285194-low group. The LOC285194-low group
had a significantly lower response to CRT than that of
LOC285194-high group(p = 0.001). In other words, pa-
tients with low expression of LOC285194 showed resis-
tance to CRT. These data suggested that LOC285194
could be a useful molecular maker for predicting the sen-
sitivity to CRT on ESCC patients. Consequently, univa-
riate analysis was then performed to determine whether
LOC285194 was a feasible molecular maker for pre-
diction of response to CRT, the results revealed that only
LOC285194 expression was associated with tumor re-
sponse to CRT (OR, 0.130; 95% CI, 0.036–0.478;
p = 0.002; Table 2). Unexpectedly, no other clinical factors
were observed to be associated with CRT response. How-
ever, age, gender, tumor size, tumor location, lymphatic
metastases, distant metastases and clinical stage trended
toward a correlation with CRT response and were in-
cluded in further multiple logistic regression analysis along
with LOC285194. Multivariate analysis indicated that low
expression of LOC285194 was the only independent risk
Figure 1 qRT-PCR analysis of lncRNA LOC285194 expression in ESCC. (A) LOC285194 was significantly down-regulated in 142 ESCC tissues,
compared to the adjacent normal tissues. Statistical differences were analyzed using paired t test. ΔCt method was used to measure the relative
LOC285194 expression, which was normalized by the GAPDH expression level. (B) LOC285194 expression was evaluated by qRT-PCR in 5 ESCC cell
lines. Normal human esophageal epithelial cell was used as control. *p < 0.05. Smaller ΔCt value indicates higher expression.
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p = 0.011, Table 2).
Association between LOC285194 expression and
prognosis after esophagectomy
Kaplan-Meier survival analysis was used to investigate
the association between the LOC285194 expression and
the prognosis of patients with ESCC after esophagec-
tomy. From the Kaplan-Meier survival curves, we found
that patients with low expression of LOC285194 had
poorer DFS (p < 0.001; Figure 2A) and OS (p < 0.001;
Figure 2B) as compared with the LOC285194-high
group. Moreover, multivariate analysis revealed that low
expression of LOC285194 (HR, 0.341; 95% CI, 0.193–
0.602; p < 0.001 and HR, 0.388; 95% CI, 0.210–0.715;
p = 0.002 for DFS and OS, respectively) as well as distant
metastasis (HR, 2.123; 95% CI, 1.063–4.240; p = 0.033
and HR, 2.389; 95% CI, 1.132–5.041; p = 0.022 for DFS
and OS, respectively) were independent prognosis fac-
tors that affected the DFS and OS of ESCC patients after
esophagectomy (Table 3).
Discussion
Esophageal squamous cell carcinoma (ESCC) is one of
the most virulent malignancies worldwide with the
5-year survival rate less than 30% [18]. Although there
have been recent improvements in combination treat-
ments including chemoradiotherapy(CRT) alone or as
an adjunct prior to surgery, local recurrences and distant
metastases are still common, and the median survival
time for ESCC patients continues to be poor. The dismal
outcomes of ESCC are largely due to our inability toselect the optimum therapy and CRT resistance [3].
Therefore, the exploration of novel molecular markers is
very important to help select patients who will benefit
from CRT as well as identify therapeutic targets.
LncRNAs are a new class of transcripts recently discov-
ered to be pervasively transcribed in human genome and
play a critical role in epigenetic regulation [19]. In
addition, as with microRNA, lncRNAs may function as
tumor markers for the prediction of tumor prognosis
[13,20]. Here we reported lncRNA LOC285194, which
was previously shown to function as a tumor suppressor
in osteosarcoma and was significantly down-regulated in
43 osteosarcoma tumor samples and 5 osteosarcoma cell
lines [14]. In addition, expression of LOC285194 deletion
in tumor was found to be associated with poor progno-
sis of osteosarcoma patients. The misexpression of this
lncRNA was also discovered in colorectal cancer, and pa-
tients with low expression of LOC285194 had a shorter
DFS [16]. This common characteristic thus strengthened
the clinical application value of LOC285194. Therefore,
we hypothesized that LOC285194 expression was also
decreased in ESCC tumor tissues and decreased of this
lncRNA may influence the treatment outcomes and could
predict the prognosis of ESCC patients.
To test this hypothesis, tissue samples from 142 pa-
tients with ESCC were selected. The qRT-PCR showed
that LOC285194 was significantly down-regulated in
ESCC tumor tissues compared to the adjacent nontumor
tissues. Furthermore, this significantly lower expression
was also discovered in 3 ESCC cell lines when compared
with that in normal esophageal epithelial cell. We then
used the median expression level of LOC285194 as a
Table 2 Univariate and multivariate logistic regression analysis of factors associated with pathologic response
Univariate analysis Multivariate analysis
Variables Case PathCR <pathCR OR 95% CI p value OR 95% CI p value
Ages
≤55 12 2 10 0.278 0.054-1.424 0.125 0.302 0.049-1.874 0.199
>55 43 18 25
Gender
Male 34 9 25 0.372 0.104-1.030 0.056 0.415 0.103-1.676 0.217
Female 21 11 10
Tumor size (cm)
≤5 35 14 21 1.556 0.482-5.019 0.460 0.617 0.131-2.905 0.541
>5 20 6 14
Tumor location
Cervical/upper thoracic 14 7 7 2.154 0.625-7.421 0.224 1.757 0.372-8.298 0.477
Middle/lower thoracic 41 13 28
Histologic grade
G1 8 3 5 0.873 0.172-4.429 0.870 nd nd nd
G2 27 11 16 1.400 0.250-7.830 0.702 nd nd nd
G3 20 6 14
T status
T1/2 14 6 8 1.446 0.419-4.997 0.560 nd nd nd
T3 41 14 27
N status
Negative 20 10 10 2.500 0.797-7.839 0.116 0.508 0.027-9.577 0.651
Positive 35 10 25
M status
M0 39 16 23 2.087 0.586-7.651 0.267 1.250 0.212-7.368 0.805
M1-lym 16 4 12
Clinical stage
IandII 21 10 11 2.182 0.705-6.756 0.176 2.102 0.109-40.483 0.623
III 34 10 24
LOC285194
low 27 4 23 0.130 0.036-0.478 0.002* 0.133 0.028-0.624 0.011*
high 28 16 12
PathCR, pathologic complete response; OR, odd ratio; CI, confidence interval; M1-lym, distant lymph node metastasis; nd, not done. *p < 0.05.
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low group and the LOC285194-high group to further in-
vestigate the association between LOC285194 expression
and clinicopathological characteristics. Patients with low
expression of LOC285194 showed larger tumor size,
worse histologic grade, advanced TNM stage, more lymph
node metastasis and distant metastases than the
LOC285194-high group. Namely, the low expression level
of LOC285194 was associated with malignant potential
and aggressive clinicopathological features in ESCC. How-
ever, the exact mechanisms behind the dysregulation of
LOC285194 expression in ESCC remain unclear. In the
study by Liu Q et al, LOC285194 was found to bespecifically induced by wild-type p53, p53 directly inter-
acted with the p53 response element in the upstream of
LOC285194 to induce its transcription [15]. Decreased ex-
pression of LOC285194 could be explained by p53 status,
because p53 mutation or deletion could account for more
than 50% of ESCC cases[21-23].
In patients with ESCC, preoperative CRT is often per-
formed as an adjuvant treatment to improve survival [24].
However, only 13–49% patients who have pathCR will
benefit from the treatment, the remaining 50% patients
present the CRT resistance[25]. To our knowledge to date,
no studies have been performed regarding the association
between lncRNA expression and the pathologic response
Figure 2 Kaplan-Meier survival analysis of association between LOC285194 expression level and (A) DFS and (B) OS of 142 ESCC
patients. Patients with low expression of LOC285194 showed decreased DFS (p < 0.001) and OS (p < 0.001 ) compared with patients with high
level of LOC285194 expression. Survival curves were compared using log-rank test.
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demonstrated for the first time that low expression of
LOC285194 was significantly negatively correlated with
pathologic response to CRT. In other words, patients with
low expression of LOC285194 suggested resistance to
CRT. Indeed, in the CRT + S group, we found that 57%
(16/28) of the LOC285194- high group had a pathCR to
CRT compared with only 15% (4/27) in the LOC285194-
low group. Therefore, our results indicated that low ex-
pression of LOC285194 could be a valuable molecular
marker for personal treatment screening of ESCC patients
before esophagectomy. In addition, rescuing the expression
of LOC285194 may have a novel clinical application in theTable 3 Multivariate cox regression analysis of independent p
survival
Disease free survival
Factors HR 95% CI
Tumor size (>5:≤5) 1.137 0.650-1.991
WHO grade (G3,G4/G1,G2) 1.019 0.607-1.981
T status (T3/T31,T2) 1.503 0.675-3.347
N status (positive/negative) 1.360 0.539-3.431
M status (M1-lym/M0) 2.123 1.063-4.240
Clinical stage (III/I + II) 1.179 0.427-3.256
LOC285194 (low/high) 0.341 0.193-0.602
HR, hazard ratio; CI, confidence interval; M1-lym, distant lymph node metastasis; *Ptreatment of ESCC patients. However, the exact me-
chanisms underlying how misexpression of LOC285194 in-
fluences the CRT sensitivity have not been fully
understood. It has been reported that LOC285194 is lo-
cated at osteo3q13.31, which harbors frequent focal copy
number alterations (CNAs) and loss of heterozygosity
(LOH) in osteosarcoma. And depletion of LOC285194
promotes osteoblast proliferation in vitro through regula-
tion of cell cycle transcripts such as cyclin D1 and VEGF/
VEGFR1 [14]. Interestingly, focal osteo3q13.31 depletion
and LOH are also found in various tumors including
esophageal cancer [26]. In addition, previous reports have
shown that up-regulation of cyclin D1, VEGF and VEGFR1redicting factors for disease free survival and overall
Overall survival
P value HR 95% CI P value
0.653 1.030 0.564-1.880 0.924
0.760 1.046 0.553-1.979 0.889
0.318 0.773 0.299-1.997 0.594
0.514 1.360 0.467-3.996 0.573
0.033* 2.389 1.132-5.041 0.022*
0.750 2.408 0.735-7.882 0.146
0.001* 0.388 0.210-0.715 0.002*
< 0.05
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ESCC patients [27,28]. Thus, we hypothesize that changes
LOC285194 might be involved in the regulation of the ex-
pression of proliferation-associated genes that in turn may
partly contribute to tumor resistance in preoperative CRT.
Clearly, further cell experiments are needed to fully under-
stand the oncogenic function of LOC285194 in human
ESCC pathogenesis, including the elucidation of which sig-
naling pathways are involved in resistance to CRT.
One of the most important findings in the present study
was the prognostic significance of LOC285194 expression
in ESCC. We observed a close association between low
expression of LOC285194 and shorter DFS and OS in pa-
tients with ESCC. Furthermore, the multivariate analysis
showed that low expression of LOC285194 was a powerful
independent prognosis factor of poor DFS and OS, which
was consistent with the previous reports in colorectal can-
cer and osteosarcoma. These findings suggested that low
expression of LOC285194 could signify a higher risk of
disease recurrence and/or treatment failure, and, that
postoperative ESCC patients should be closely monitored
and receive effective adjuvant therapies.
Conclusion
Our study shown that LOC285194 expression was signifi-
cantly down-regulated in ESCC tumor tissues and cell
lines, and low expression of LOC285194 was associated
with CRT resistance and poor prognosis. Furthermore, de-
creased expression of LOC285194 could potentially serve
as a molecular marker to predict the clinical outcomes
(shorter DFS and OS) of ESCC patients after surgery, and
select patients who will benefit from the preoperative
CRT.
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